piwik-script

Intern
    Onkologische Forschung

    Translational Next Generation Sequencing

    Drivers of melanoma progression under therapy
    (collaboration between Physiological Chemistry, Dermatology, Bioinformatics Unit CCC, Human Genetics, Pathology)

    Summary:

    Our project aims to identify driver mutations and tumor modifiers of primary and metastatic melanomas, using next generation sequencing of a self-designed melanoma-relevant gene panel, RNA analysis and protein analysis of histological sections. By comprehensive analysis of altered genes on DNA and expression level, we can identify cancer-promoting changes. One focus of the study is the evolution of melanoma during progression and during the course of conventional melanoma therapy with BRAF/MEK and checkpoint inhibitors.

    Meierjohann S: Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-017-9659-z. (2017) (epub ahead of print)

    Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M, Meierjohann S: The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget 5:5040-5053 (2014)

    Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S: Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. 133:1601-1609 (2013)

    Kontakt

    Comprehensive Cancer Center Mainfranken
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin